Amplia Therapeutics Limited
INNMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.47 | 0.12 | -0.10 | -1.13 |
| FCF Yield | -28.60% | -34.34% | -28.15% | -21.23% |
| EV / EBITDA | -1.95 | -2.88 | -1.63 | -2.28 |
| Quality | ||||
| ROIC | -30.94% | -17.13% | -34.16% | -15.21% |
| Gross Margin | 94.43% | 90.07% | 93.83% | 99.84% |
| Cash Conversion Ratio | – | 1.14 | 0.85 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 47.07% | 30.94% | -8.12% | 286.97% |
| Free Cash Flow Growth | -34.28% | 3.35% | -20.17% | -51.16% |
| Safety | ||||
| Net Debt / EBITDA | 1.60 | 0.39 | 0.96 | 3.44 |
| Interest Coverage | 0.00 | -56.38 | -114.93 | -3,167.88 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,347.44 | -1,063.63 | -1,375.32 | -41,619.78 |